After decades with no approved therapy, the FSGS treatment landscape is changing within a compressed window. Travere’s Filspari (sparsentan) is newly approved by the FDA as of April 13, 2026, DMX-200 is advancing through Phase 3, and a pipeline of targeted agents is closing behind them. Based on quantitative and qualitative primary research with U.S. nephrology KOLs conducted in March 2026, REACH has identified three strategic implications that matter for anyone operating in this space.
FSGS is a basket diagnosis and that creates both risk and opportunity
FSGS is not a single disease. It is a histologic pattern characterized by focal scarring of some glomeruli, segmental within the tuft that represents the shared downstream endpoint of at least four distinct etiologic pathways: primary (idiopathic/immune-mediated), secondary (adaptive/hemodynamic), genetic (podocyte structural mutations), and emerging APOL1-mediated disease as a distinct patient segment. The histologic classification was built by pathologists in the 1960s, and while it remains the clinical and regulatory currency today, the field is actively moving toward etiologic definition which in turn will impact treatment selection as new therapies arrive.
This matters commercially because a trial that enrolls all FSGS patients by histology may be treating patients whose underlying mechanism the drug cannot affect. The historical late-stage drug development failures in FSGS is at least partly attributable to this. Companies entering the space with a mechanism-specific asset need a clear enrollment strategy. Those with final-common-pathway agents have a broader addressable population but face a less differentiated positioning story as the field fragments.
Sparsentan will define the treatment algorithm for years
REACH’s research reveals that sparsentan is mostly to be positioned as the 2L standard in primary FSGS following ACEi/ARB failure, constrained there initially by step therapy requirements but with meaningful pull toward earlier use in newly diagnosed patients with high proteinuria burden. The clinical logic is compelling: most FSGS patients fail 1L RAAS blockade if failure is defined as achieving near-normal proteinuria, which means sparsentan’s addressable population is large.
The commercial position is further reinforced by first-mover advantage. Travere will have at minimum a year (likely more) before any direct competitor reaches the market. By the time BioMarin’s DMX-200 launches, nephrologists will be experienced with sparsentan in FSGS (building off experience with the drug in IgA nephropathy), step therapy protocols will be embedded, and the path for subsequent agents stands to narrow accordingly.
According to KOLs, the failure to achieve the primary eGFR slope endpoint in the DUPLEX trial at 108 weeks does not materially weaken sparsentan’s initial position in a field where no approved alternative exists.
Genetic testing is now infrastructure and is reshaping the addressable market
The near-universal adoption of genetic testing in FSGS, driven substantially by the Natera Renasight panel (sponsored by Vertex) is changing how patients are classified, enrolled in trials, and routed to therapy. Several commercial implications follow directly.
For genetically targeted assets, the patient identification infrastructure is materially better than it was three years ago. Earlier genetic testing means APOL1 and TRPC6 populations are being identified earlier in the disease course before transplant, before trial enrollment, and sometimes before biopsy. Vertex has effectively pre-invested in this infrastructure, and companies developing assets in the APOL1 or podocyte genetics space are benefiting from it.
For broad-label assets arriving later in the pipeline, genetic segmentation creates a more complicated positioning environment. As APOL1-targeted therapy, TRPC6 inhibition, and anti-nephrin antibody testing gain clinical traction, the undifferentiated “primary FSGS” population will shrink. Assets that cannot claim a specific mechanism or patient segment will face increasing competition for a narrowing slice of the market, unless positioned as part of foundational/supportive treatment used across primary and genetic FSGS.
The analogy REACH finds highly instructive is membranous nephropathy, where identification of the PLA2R antigen transformed an undifferentiated disease into a precision-treatable condition for 70-80% of patients. FSGS will not reorganize as cleanly given that the etiology is more heterogeneous, but the directional shift is the same. Companies developing assets two to three years out should be stress-testing their positioning against a more fragmented, etiology-defined landscape, not the current primary FSGS umbrella.
The FSGS market is entering a period of rapid change within a narrow window. The sequence in which therapies arrive, the payer environment they enter, and the genetic testing infrastructure now in place will jointly determine which assets find durable commercial positions and which find themselves crowded out before the market stabilizes.
REACH Market Research specializes in physician intelligence for rare and niche diseases – the markets where published literature is sparse, trial populations are small, and the only intelligence that exists is inside the heads of the specialists who actually treat these patients. This analysis is based on seven in-depth KOL interviews and a quantitative survey of 25 nephrologists conducted in March 2026 as part of REACH’s ongoing primary research program in rare nephrology.
Learn more about the MarketVue® (U.S.) Focal Segmental Glomerulosclerosis (FSGS) report or request access below.